Therapeutic resistance arises from multiple interconnected factors: AR splice variants (particularly AR-V7) enable ligand-independent AR activity [4], metabolic reprogramming allows adaptation to therapeutic pressure [5], and the immunosuppressive tumor microenvironment facilitates treatment evasion [6]. Here, AR is linked to neoplasm.